Acasă › Cancer de sân › California › Orange
Studii clinice pentru Cancer de sân în Orange, CA
14 studii pentru Cancer de sân caută participanți în și în jurul orașului Orange (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
În curs de recrutareFaza 3
- UC Irvine Medical Center, Orange
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
În curs de recrutareFaza 1/2
- University of California Irvine, Orange
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
În curs de recrutareFaza 2
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
În curs de recrutareFaza 2
- Community Clinical Trials, Orange
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
În curs de recrutareFaza 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
În curs de recrutareFaza 3
- UC Irvine Health, Chao Family Comprehensive Cancer Center, Orange
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
În curs de recrutareFaza 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
E-Mindfulness Approaches for Living After Breast Cancer
În curs de recrutareFaza 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
În curs de recrutareFaza 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
În curs de recrutareFaza 1/2
- UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
În curs de recrutareFaza 3
- Saint Joseph Hospital - Orange, Orange
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
În curs de recrutareFaza 2
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
În curs de recrutareFaza 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
În curs de recrutareStudiu observațional
- Massive Bio SYNERGY-AI site, Orange
Studii pentru Cancer de sân în alte orașe
- New York City, NY136 studii
- Houston, TX126 studii
- Boston, MA112 studii
- Nashville, TN81 studii
- Los Angeles, CA73 studii
- Edison, NJ68 studii
- St. Louis, MO64 studii
- Queens, NY64 studii
- Durham, NC64 studii
- Chicago, IL59 studii
- Philadelphia, PA56 studii
- Dallas, TX55 studii
Alte studii în Orange
- Cancer pulmonar cu celule non-pătrate25 studii
- Cancer metastatic20 studii
- Cancer colorectal16 studii
- Cancer ovarian16 studii
- Cancer pancreatic15 studii
- Melanom14 studii
- Cancer hepatic (carcinom hepatocelular)14 studii
- Cancer pulmonar14 studii
- Cancer de prostată14 studii
- Cancer gastric13 studii
- Cancer (toate tipurile)13 studii
- Leucemie mieloasă acută13 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.